Working… Menu

Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00715091
Recruitment Status : Completed
First Posted : July 15, 2008
Last Update Posted : August 25, 2014
Information provided by (Responsible Party):
J. Sieper, Charite University, Berlin, Germany

Brief Summary:
This is a randomised, controlled, multi-centre clinical trial on AS patients. Experimental intervention: continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren Resinate), divided into 75mg Voltaren twice dailyControl intervention: treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment strategy of the control intervention (on-demand) reflects current clinical practice in AS. Duration of intervention per patient: 2 years Follow-up per patient: safety assessment 3 months after termination of the trial.

Condition or disease Intervention/treatment Phase
Ankylosing Spondylitis Drug: diclophenac Phase 4

Detailed Description:
Ankylosing spondylitis (AS) is a common chronic inflammatory rheumatic disease with a prevalence of about 0.5%. First symptoms normally occur in young adulthood. Early in its course, AS is dominated by chronic pain, fatigue and morning stiffness, later on by ankylosis and loss of function. Nonsteroidal anti-inflammatory drugs (NSAID) and tumor necrosis factor (TNF) alpha blocking agents are the only drugs with proven efficacy for signs and symptoms. It is not clear, however, whether these drugs are also capable of retarding or stopping structural damage, i.e. prevention of bony ankylosis. Earlier investigations indicated that NSAIDs have, in addition to their anti-inflammatory, also an anti-osteoproliferative effect. In this study we will investigate whether treatment with 150 mg diclofenac, a non-selective NSAID, on a daily basis (continuous treatment) over 2 years is capable to slow down the development of bony ankylosis as compared to treatment with 75-150mg diclofenac as needed according to clinical symptoms (on-demand treatment). In this national multi-centre randomized trial patients with symptomatic AS and indication for NSAID therapy will be enrolled in about 40 centres. The primary outcome parameter is the proportion of patients with radiographic progression in the spine after 2 years in each treatment arm. If continuous NSAID treatment results in less radiographic progression as compared to on-demand treatment, a true disease modifying effect of NSAID has to be assumed which will most likely change the place of NSAID treatment in AS.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial
Study Start Date : September 2008
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Arm Intervention/treatment
Experimental: 1
continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren Resinate), divided into 75mg Voltaren twice daily
Drug: diclophenac
continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
Other Name: voltaren resinat

Active Comparator: 2
treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment strategy of the control intervention (on-demand) reflects current clinical practice in AS.
Drug: diclophenac
treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
Other Name: Voltaren resinate

Primary Outcome Measures :
  1. radiographic change (mean) of the spine after 2 years in the per-protocol population. Radiographs will be collected and centrally digitized. Scoring will be done by 2 readers who were blinded to treatment and sequence of the films [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. the proportions of patients with any progression (change in the mSASSS ≥ 1) and change in the mSASSS > smallest detectable change (SDC), i.e. change in mSASSS which is greater than the measurement error. [ Time Frame: 2 years ]
  2. ITT analysis of radiographic change. [ Time Frame: 2 years ]
  3. Change in VAS back pain, BASDAI, BASFI, BASMI, CRP. [ Time Frame: 2 years ]
  4. event rates of serious and non-serious adverse events will be documented and compared between the two groups. [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • AS according to mod. New York criteria
  • Patients must have radiographic damage (at least one syndesmophyte) of the spine but no complete ankylosis of the cervical and lumbar spine (these are patients at risk for further and more rapid radiographic progression)
  • Patients must have active disease at inclusion defined as BASDAI question 2 (related to back pain) >= 4 (VAS, range 0-10) without NSAID treatment and with a clinical indication for NSAID therapy based on signs and symptoms

Exclusion Criteria:

  • No radiographic damage (syndesmophyte) of the spine at baseline
  • Complete ankylosis of the cervical and lumbar spine
  • Inactive disease
  • Evidence of current or past peptic ulcer
  • Current or past coronary heart disease
  • Stroke or transient ischemic attack
  • Uncontrolled hypertension
  • Chronic renal failure (creatinine > 1.5mg/dl)
  • Impaired liver function
  • Pregnancy
  • Abnormal liver function (2x upper limit of normal)
  • Active hepatitis B or C, chronic or acute heart failure (NYHA III or IV) -
  • History of HIV infection
  • History of neoplastic disease (details please refer to exclusion criteria)
  • History of abuse of "hard" drugs or alcoholism
  • Concomitant treatment with steroids, TNF-blockers, other DMARDs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00715091

Layout table for location information
Medizinische Universitätsklinik Innere Medizin
Tübingen, Baden-Württemberg, Germany, 1072076
Praxis Dr. Jacki
Tübingen, Baden-Württemberg, Germany, 72072
Praxis Dr. Manger
Bamberg, Bayern, Germany, 96047
Praxis Dr. Ochs
Bayreuth, Bayern, Germany, 95445
Praxis Dr. Kellner
München, Bayern, Germany, 80639
Praxiszentrum St. Bonifazius
München, Bayern, Germany, 81541
Gemeinschaftspraxis Dr. Göttl
Passau, Bayern, Germany, 94032
Fachklinik Bad Bentheim
Bad Bentheim, Niedersachsen, Germany, 48455
Praxis Dr. Rockwitz
Goslar, Niedersachsen, Germany, 38640
Gemeinschaftspraxis Dr. von Hinüber
Hildesheim, Niedersachsen, Germany, 31134
Gemeinschaftspraxis Dr. Gauler
Osnabrück, Niedersachsen, Germany, 49076
Praxis Dr. Dockhorn
Weener, Niedersachsen, Germany, 26828
Universitätsklinikum DüsseldorfKlink für Endokrinologie, Diabetologie und Rheumatologie
Düsseldorf, Nordrhein-Westfalen, Germany, 40001
Rheumatologische Schwerpunktpraxis
Düsseldorf, Nordrhein-Westfalen, Germany, 40217
Evangelisches Krankenhaus
Ratingen, Nordrhein-Westfalen, Germany, 40882
Praxis Dr. Kramer
Remscheid, Nordrhein-Westfalen, Germany, 42897
Praxis Dr. Schoo
Rheine, Nordrhein-Westfalen, Germany, 48431
Rheumatologische Praxis Dr. Spieler
Zerbst, Sachsen-Anhalt, Germany, 39261
Berlin, Germany, 12163
Praxis Mielke
Berlin, Germany, 12627
Praxis Zinke
Berlin, Germany, 13055
Gemeinschaftspraxis Dr. Schwenke
Dresden, Germany, 01109
Praxis Dr. Pick
Grafschaft bei Bad Neuenahr-Ahrweiler, Germany, 53501
Praxis Dr. Kühne
Haldensleben, Germany, 39340
Rheumazentrum Ruhrgebiet, St. Josefs Krankenhaus
Herne, Germany, 44652
St. Josefs-Krankenhaus, Rheumatologie
Herne, Germany, 44652
Praxis Dr. Kapelle
Hoyerswerda, Germany, 02977
Gemeinschaftspraxis Dr. Kolitsch
Katzhütte, Germany, 98746
Praxis Dr. Gräßler
Pirna, Germany, 01796
Praxis Bohl-Bühler
Potsdam, Germany, 14469
Sponsors and Collaborators
Charite University, Berlin, Germany
Layout table for investigator information
Principal Investigator: Martin Rudwaleit, MD Charité University, Berlin, Germany
Principal Investigator: Joachim Sieper, MD Charité University, Berlin, Germany
Principal Investigator: Jürgen Braun, MD Rheumazentrum Ruhrgebiet, Herne, Germany

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: J. Sieper, Prof., Charite University, Berlin, Germany Identifier: NCT00715091     History of Changes
Other Study ID Numbers: ENRADAS-01
EUDA-CT: 2007-007637-39
First Posted: July 15, 2008    Key Record Dates
Last Update Posted: August 25, 2014
Last Verified: August 2014
Keywords provided by J. Sieper, Charite University, Berlin, Germany:
ankylosing spondylitis
radiographic changes
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis, Ankylosing
Bone Diseases, Infectious
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Joint Diseases
Cholestyramine Resin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticholesteremic Agents
Hypolipidemic Agents
Lipid Regulating Agents